Literature DB >> 12742467

Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience.

E Morelon1, H Kreis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12742467     DOI： 10.1016/s0041-1345(03)00244-6

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  12 in total

Review 1.  Benefit-risk assessment of sirolimus in renal transplantation.

Authors:  Dirk R J Kuypers
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  microRNA-181a downregulates deptor for TGFβ-induced glomerular mesangial cell hypertrophy and matrix protein expression.

Authors:  Soumya Maity; Amit Bera; Nandini Ghosh-Choudhury; Falguni Das; Balakuntalam S Kasinath; Goutam Ghosh Choudhury
Journal:  Exp Cell Res       Date:  2018-02-01       Impact factor: 3.905

3.  Stable renal function after islet transplantation: importance of patient selection and aggressive clinical management.

Authors:  Cristiane B Leitão; Pablo Cure; Shari Messinger; Antonello Pileggi; Oliver Lenz; Tatiana Froud; Raquel N Faradji; Gennaro Selvaggi; Warren Kupin; Camillo Ricordi; Rodolfo Alejandro
Journal:  Transplantation       Date:  2009-03-15       Impact factor: 4.939

Review 4.  mTOR inhibitors and renal allograft: Yin and Yang.

Authors:  Gianluigi Zaza; Simona Granata; Paola Tomei; Valentina Masola; Giovanni Gambaro; Antonio Lupo
Journal:  J Nephrol       Date:  2014-05-08       Impact factor: 3.902

5.  Renal cortex neuronal nitric oxide synthase in response to rapamycin in kidney transplantation.

Authors:  You-Lin Tain; Veronika Muller; Attila J Szabo; Aaron Erdely; Cheryl Smith; Chris Baylis
Journal:  Nitric Oxide       Date:  2007-10-12       Impact factor: 4.427

Review 6.  Sirolimus-associated proteinuria and renal dysfunction.

Authors:  Gopala K Rangan
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

7.  TGFβ-induced deptor suppression recruits mTORC1 and not mTORC2 to enhance collagen I (α2) gene expression.

Authors:  Falguni Das; Amit Bera; Nandini Ghosh-Choudhury; Hanna E Abboud; Balakuntalam S Kasinath; Goutam Ghosh Choudhury
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

8.  Sirolimus conversion efficacy for graft function improvement and histopathology in renal recipients with mild to moderate renal insufficiency.

Authors:  Dong Jin Joo; Chul Woo Yang; Hyeon Joo Jeong; Beom Jin Lim; Kyu Ha Huh; Byung Ha Chung; Yeong Jin Choi; Shin-Wook Kang; Yu Seun Kim
Journal:  J Korean Med Sci       Date:  2014-07-30       Impact factor: 2.153

9.  Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects.

Authors:  Daniel Abramowicz; Karine Hadaya; Marc Hazzan; Nilufer Broeders; Anh-Dung Hoang; Lidia Ghisdal; Christian Noel; Karl Martin Wissing
Journal:  Nephrol Dial Transplant       Date:  2008-06-20       Impact factor: 5.992

10.  Cellular effects of everolimus and sirolimus on podocytes.

Authors:  Sandra Müller-Krebs; Lena Weber; Julia Tsobaneli; Lars P Kihm; Jochen Reiser; Martin Zeier; Vedat Schwenger
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.